Institute for Wealth Management LLC. Sells 1,359 Shares of Sanofi SA (NYSE:SNY)

Institute for Wealth Management LLC. lowered its position in Sanofi SA (NYSE:SNY) by 6.9% in the 2nd quarter, Holdings Channel reports. The fund owned 18,269 shares of the company’s stock after selling 1,359 shares during the quarter. Institute for Wealth Management LLC.’s holdings in Sanofi were worth $933,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of SNY. Bank of New York Mellon Corp boosted its stake in Sanofi by 2.2% during the 4th quarter. Bank of New York Mellon Corp now owns 411,980 shares of the company’s stock valued at $20,682,000 after purchasing an additional 8,703 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Sanofi by 4.3% in the 4th quarter. Geode Capital Management LLC now owns 220,607 shares of the company’s stock worth $11,074,000 after buying an additional 9,114 shares during the last quarter. Verus Capital Partners LLC purchased a new position in shares of Sanofi in the 4th quarter worth $73,000. Ellevest Inc. boosted its stake in shares of Sanofi by 172.4% in the 1st quarter. Ellevest Inc. now owns 2,397 shares of the company’s stock worth $105,000 after buying an additional 1,517 shares during the last quarter. Finally, Reilly Financial Advisors LLC boosted its stake in shares of Sanofi by 7.2% in the 1st quarter. Reilly Financial Advisors LLC now owns 45,600 shares of the company’s stock worth $1,994,000 after buying an additional 3,060 shares during the last quarter. Institutional investors own 7.04% of the company’s stock.

Sanofi stock traded down $0.05 during trading on Friday, reaching $52.45. The company had a trading volume of 2,802,341 shares, compared to its average volume of 2,018,114. The company has a current ratio of 1.22, a quick ratio of 0.85 and a debt-to-equity ratio of 0.40. The firm’s 50-day simple moving average is $51.68 and its 200 day simple moving average is $48.67. The firm has a market capitalization of $131.34 billion, a price-to-earnings ratio of 16.76, a price-to-earnings-growth ratio of 2.41 and a beta of 0.67. Sanofi SA has a 52 week low of $37.62 and a 52 week high of $55.00.

A number of equities analysts have recently issued reports on SNY shares. Zacks Investment Research upgraded Sanofi from a “hold” rating to a “buy” rating and set a $50.00 price target on the stock in a research note on Monday, May 18th. Barclays restated an “equal weight” rating on shares of Sanofi in a research note on Tuesday, April 28th. JPMorgan Chase & Co. restated an “overweight” rating on shares of Sanofi in a research note on Friday. Morgan Stanley reaffirmed an “overweight” rating on shares of Sanofi in a report on Tuesday, June 9th. Finally, UBS Group reaffirmed a “buy” rating on shares of Sanofi in a report on Tuesday, May 26th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $54.00.

In other Sanofi news, major shareholder Sanofi sold 120,234 shares of the firm’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $597.48, for a total transaction of $71,837,410.32. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.00% of the stock is owned by company insiders.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

See Also: Buyback

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.